FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280622> ?p ?o ?g. }

• W4379280622 endingPage "11517" @default.
• W4379280622 startingPage "11517" @default.
• W4379280622 abstract "11517 Background: New treatment options are needed for sarcomas. Lenvatinib (L) is an oral, multi-tyrosine kinase inhibitor with significant inhibitory activity against VEGF receptor (VEFGR) 1-3, FGF receptor (FGFR) 1-3, KIT, platelet-derived growth factor receptor (PDGFR) alpha/beta, and RET. Experimental models suggest that L can favorably alter the tumor immune environment, and the combination of L and pembrolizumab (P) has proven to be synergistic and effective across multiple solid tumor types, providing rationale for this study. Methods: This is a pilot study evaluating the efficacy of L and P in select sarcomas. Patients who had at least 1 prior regimen but ≤ 3 were enrolled into one of five cohorts (n = 10 each) A: leiomyosarcoma (LMS); B: undifferentiated pleomorphic sarcoma (UPS); C: angiosarcoma and epithelioid hemangioendothelioma (EHE); D: synovial sarcoma (SS) and malignant peripheral nerve sheath tumor (MPNST); and E: osteosarcoma (OS) and chondrosarcoma (CS). Patients were treated with an initial 2-week run-in of L 20 mg orally daily. Subsequently, P was administered at 200 mg IV every 21 days. The primary endpoint for each cohort was the best objective response rate (ORR) documented by RECIST v1.1 by 27 weeks. The combination was considered worthy of further study if 2 or more responses were observed in a cohort. Secondary endpoints included progression-free survival (PFS), overall survival, duration of response, and safety of the combination. Archival tissue and on-treatment biopsies were collected. Results: As of January 31 st , 2023, cohorts A, D and E have completed accrual. The best response in the LMS cohort was stable disease (SD). In cohort D there were 3 partial responses (PR): 2 SS; 1 radiation associated high grade MPNST. In cohort E one of 6 patients with OS had a PR. To date, of the 6 patients with angiosarcoma, there was 1 PR in a patient with adrenal primary that occurred after the prespecified 27-week timepoint. One of 5 evaluable patients in Cohort B had a PR. Among the 44 patients evaluable for safety, most common AEs were hypertension (56.8%), diarrhea (45.5%), proteinuria (45.5%), fatigue (40.9%), headache (36.4%) and nausea (36.4%). Most common ≥ grade 3 AEs were hypertension (13.6%), dyspnea (6.8%), non-cardiac chest pain (6.8%), syncope (6.8%). Conclusions: A signal of activity was noted in this pilot study for patients with OS, MPNST, angiosarcoma and SS. In the LMS cohort, there were no responses, and PFS was poor. Enrollment to cohorts B and C is ongoing. Clinical trial information: NCT04784247 . [Table: see text]" @default.
• W4379280622 created "2023-06-05" @default.
• W4379280622 creator A5000721929 @default.
• W4379280622 creator A5005037311 @default.
• W4379280622 creator A5006374965 @default.
• W4379280622 creator A5006782265 @default.
• W4379280622 creator A5010913859 @default.
• W4379280622 creator A5012215691 @default.
• W4379280622 creator A5031037291 @default.
• W4379280622 creator A5032196793 @default.
• W4379280622 creator A5034595315 @default.
• W4379280622 creator A5043833554 @default.
• W4379280622 creator A5045094375 @default.
• W4379280622 creator A5057908620 @default.
• W4379280622 creator A5064214267 @default.
• W4379280622 creator A5067158281 @default.
• W4379280622 creator A5073766539 @default.
• W4379280622 creator A5078755190 @default.
• W4379280622 creator A5088495181 @default.
• W4379280622 creator A5089731384 @default.
• W4379280622 creator A5092083119 @default.
• W4379280622 date "2023-06-01" @default.
• W4379280622 modified "2023-09-23" @default.
• W4379280622 title "A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma." @default.
• W4379280622 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.11517" @default.
• W4379280622 hasPublicationYear "2023" @default.
• W4379280622 type Work @default.
• W4379280622 citedByCount "0" @default.
• W4379280622 crossrefType "journal-article" @default.
• W4379280622 hasAuthorship W4379280622A5000721929 @default.
• W4379280622 hasAuthorship W4379280622A5005037311 @default.
• W4379280622 hasAuthorship W4379280622A5006374965 @default.
• W4379280622 hasAuthorship W4379280622A5006782265 @default.
• W4379280622 hasAuthorship W4379280622A5010913859 @default.
• W4379280622 hasAuthorship W4379280622A5012215691 @default.
• W4379280622 hasAuthorship W4379280622A5031037291 @default.
• W4379280622 hasAuthorship W4379280622A5032196793 @default.
• W4379280622 hasAuthorship W4379280622A5034595315 @default.
• W4379280622 hasAuthorship W4379280622A5043833554 @default.
• W4379280622 hasAuthorship W4379280622A5045094375 @default.
• W4379280622 hasAuthorship W4379280622A5057908620 @default.
• W4379280622 hasAuthorship W4379280622A5064214267 @default.
• W4379280622 hasAuthorship W4379280622A5067158281 @default.
• W4379280622 hasAuthorship W4379280622A5073766539 @default.
• W4379280622 hasAuthorship W4379280622A5078755190 @default.
• W4379280622 hasAuthorship W4379280622A5088495181 @default.
• W4379280622 hasAuthorship W4379280622A5089731384 @default.
• W4379280622 hasAuthorship W4379280622A5092083119 @default.
• W4379280622 hasConcept C121608353 @default.
• W4379280622 hasConcept C126322002 @default.
• W4379280622 hasConcept C142724271 @default.
• W4379280622 hasConcept C143998085 @default.
• W4379280622 hasConcept C2776264508 @default.
• W4379280622 hasConcept C2776910622 @default.
• W4379280622 hasConcept C2777701055 @default.
• W4379280622 hasConcept C2778256501 @default.
• W4379280622 hasConcept C2778439243 @default.
• W4379280622 hasConcept C2779490328 @default.
• W4379280622 hasConcept C2779761222 @default.
• W4379280622 hasConcept C2780057760 @default.
• W4379280622 hasConcept C71924100 @default.
• W4379280622 hasConcept C72563966 @default.
• W4379280622 hasConceptScore W4379280622C121608353 @default.
• W4379280622 hasConceptScore W4379280622C126322002 @default.
• W4379280622 hasConceptScore W4379280622C142724271 @default.
• W4379280622 hasConceptScore W4379280622C143998085 @default.
• W4379280622 hasConceptScore W4379280622C2776264508 @default.
• W4379280622 hasConceptScore W4379280622C2776910622 @default.
• W4379280622 hasConceptScore W4379280622C2777701055 @default.
• W4379280622 hasConceptScore W4379280622C2778256501 @default.
• W4379280622 hasConceptScore W4379280622C2778439243 @default.
• W4379280622 hasConceptScore W4379280622C2779490328 @default.
• W4379280622 hasConceptScore W4379280622C2779761222 @default.
• W4379280622 hasConceptScore W4379280622C2780057760 @default.
• W4379280622 hasConceptScore W4379280622C71924100 @default.
• W4379280622 hasConceptScore W4379280622C72563966 @default.
• W4379280622 hasIssue "16_suppl" @default.
• W4379280622 hasLocation W43792806221 @default.
• W4379280622 hasOpenAccess W4379280622 @default.
• W4379280622 hasPrimaryLocation W43792806221 @default.
• W4379280622 hasRelatedWork W2061292442 @default.
• W4379280622 hasRelatedWork W2507857663 @default.
• W4379280622 hasRelatedWork W2914613572 @default.
• W4379280622 hasRelatedWork W3041438363 @default.
• W4379280622 hasRelatedWork W3172653328 @default.
• W4379280622 hasRelatedWork W3183140313 @default.
• W4379280622 hasRelatedWork W4200199918 @default.
• W4379280622 hasRelatedWork W4309861866 @default.
• W4379280622 hasRelatedWork W4328052611 @default.
• W4379280622 hasRelatedWork W4379280622 @default.
• W4379280622 hasVolume "41" @default.
• W4379280622 isParatext "false" @default.
• W4379280622 isRetracted "false" @default.
• W4379280622 workType "article" @default.